Huntsman clears HSR, but its fixed-share merger still fails the long 10/5 gate

Summary: Huntsman (NYSE: HUN) and Olin (NYSE: OLN) received expiration of the Hart-Scott-Rodino waiting period, and both shareholder votes were already approved. Huntsman holders will receive 0.5476 Olin shares. At current references of $9.54 for HUN and $17.20 for OLN, the implied consideration is about $9.42, below HUN's price before fees. The proposed $400 million-plus synergy case remains long-dated, leverage is material, and the merger can still fail other conditions. This is one research article, not an executable long. The paired signal is watch, with entry.price: null and execution.can_execute: false.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	Huntsman (HUN)	Long	HSR cleared and synergy thesis versus negative current exchange spread	Sep. 11 HSR release and Sep. 11 tape	Remaining approvals and close	Direct positioning unavailable	Reject: base -1.2%, adverse -26.6%, negative EV	Liquid, live exit audit missing	Deal break, leverage, chemicals cycle
2	Olin (OLN)	Long	Scale and synergies versus integration and debt	Sep. 11 HSR release	Close and deleveraging	Positioning unavailable	Reject	Liquid, prior event screen	Leverage, cycle, integration
3	EFSI	Long	Fixed-share bank merger spread	Sep. 8 agreement	Approvals and close	Positioning unavailable	Reject	Thin, prior screen	Break value, credit

Selected opportunity: Huntsman, for research only.

Why this one now: HSR expiry is a new, dated change in the closing path. It materially reduces one regulatory uncertainty but does not repair the negative spread or the leverage and chemical-cycle risks.

What should surprise the reader: Regulatory progress can be bullish for completion and still leave the target over its current exchange value. The fixed ratio transfers Olin's share-price risk directly to Huntsman holders.

Why This Is the Best Opportunity Right Now

Olin and Huntsman announced that the HSR waiting period expired on September 11, satisfying a key closing condition. Shareholders of both companies approved the merger on August 25. Huntsman holders receive 0.5476 Olin shares, and the companies target a first-half 2027 close. The combined company is expected to generate more than $400 million of cost synergies and integration benefits. HSR expiry release

Why This Can Move More Than 5% Soon

The remaining catalysts are foreign-investment and other regulatory approvals, final closing, integration, and deleveraging. HUN's latest regular-session reference was $9.54 at 2026-09-11T23:15:00Z, while OLN was $17.20. The implied 0.5476× value is $9.42, a negative 1.2% spread. HUN reference and OLN reference

10/5 Asymmetry Gate

The map uses a $9.54 HUN reference. A top target of $12 assumes the combined company earns the synergy case and the chemical cycle recovers. The $9.42 base target is the current 0.5476× OLN value. The $7 bottom case reflects a deal break, leverage, or weaker chemical demand.

Input	Result
Base move to $9.42	-1.26%
Credible adverse move to $7	-26.62%
Gross reward / adverse risk	negative
Probability-weighted expected move	-8.00%
10/5 status	Reject

The base payoff is negative at current references, expected value is negative, and break risk exceeds 5% by a wide margin.

What Should Surprise the Reader

The HSR milestone is progress, not a cash bid. Huntsman holders receive stock in a loss-making, leveraged chemical company, and the exchange ratio does not protect them if OLN falls before closing.

The Setup

Huntsman and Olin are combining into OlinHuntsman, a vertically integrated North American chemicals company. The long hypothesis is that chlorine, epoxy, polyurethane, and ammunition scale create cost and portfolio synergies. The counterweight is cyclical demand, debt, integration, and fixed-share consideration.

The Market Price

HUN's latest reference was $9.54 at 2026-09-11T23:15:00Z; OLN was $17.20 at the same observation. HUN traded $9.48-$9.75 on 1.64 million shares and OLN $17.11-$17.68 on 2.38 million shares. Spread, depth, venue quality, settlement, and exit liquidity were not verified.

The Mispricing

The market may underprice the value of HSR clearance and the future $400 million-plus synergy case. The counterview is that HUN already trades above the fixed exchange value, so current holders pay for completion while receiving no premium. The disagreement is synergy value versus break and OLN price risk.

The Positioning

Direct current positioning, borrow terms, and dealer exposure were not reliably available. Event volume is observable but cannot distinguish merger accumulation from risk reduction. Positioning confidence is low.

The Catalyst

Remaining approvals: verify foreign-investment and other regulatory conditions, final filings, and closing date.
Exchange-ratio bridge: track OLN price, 0.5476× consideration, and any share-count changes.
Synergy and deleveraging: verify the $400 million-plus cost-savings case, integration costs, debt, cash flow, and chemical volumes.

The cheapest falsification is a pre-close filing showing additional regulatory conditions or a lower synergy case. That would widen the already negative spread.

The Payoff

The top case requires OLN appreciation and synergy delivery. The base case is the current exchange value and is negative for HUN holders. The bottom case is a deal break or chemical-cycle reset.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	25%	$12.00	+25.79%	Through first post-close report	OLN rises and synergies arrive	Low-Medium
Base Case	50%	$9.42	-1.26%	Through close	Exchange ratio holds and deal closes	High
Bottom Case	25%	$7.00	-26.62%	Same window	Deal break, leverage, or chemical weakness	Medium
Invalidation	n/a	Merger fails	Thesis invalidated	Before close	Remaining condition fails	High

Probability-weighted expected value: $8.78, or -8.00% before costs.

Current market level and timestamp: $9.54 HUN and $17.20 OLN at 2026-09-11T23:15:00Z.

Primary instrument: HUN common stock only, unlevered.

10/5 favorable base move: -1.26% from the reference, not an executable entry.

10/5 credible adverse move: -26.62% from the reference.

10/5 measurement basis: reference-only.

10/5 status: Reject.

Confidence: Medium-low. The HSR milestone is primary and fresh, but remaining approvals, integration, leverage, and live execution evidence are incomplete.

The Kill Shot

The strongest counterparty view is that HSR expiry and shareholder approval leave only routine closing work before a $400 million-plus synergy platform emerges. The load-bearing assumption is that OLN's share price and chemical cash flows remain stable through close. If either fails, HUN holders absorb the downside.

What Could Go Wrong

Remaining approvals can fail; closing can slip; Olin's leverage can rise; chemical demand and pricing can weaken; integration costs can exceed plan; and the fixed ratio can transfer OLN's equity decline to HUN. Gaps, halts, slippage, spread widening, and thin exit liquidity can bypass any planned loss limit.

What Would Prove This Wrong

The long screen is invalid if the merger is delayed, OLN falls, synergy estimates are cut, debt rises, or chemical volumes weaken. HSR expiry alone does not establish shareholder value.

Risk Audit

Evidence: HSR expiry and merger terms are primary; live market structure is incomplete.
Spread: current exchange value is approximately 1.2% below HUN's reference.
Leverage: both chemical companies remain cycle-sensitive and debt-bearing.
Positioning: direct current positioning is unavailable.
Execution: entry.price remains null and execution is blocked. No options, leverage, margin, market order, or price-floor expression is supported.

Best Trade Strategy

There is no trade-qualified strategy in this run. Keep HUN on a research watch only. Re-open after remaining approvals and closing if the exchange ratio, OLN price, synergy, debt, cash flow, and chemical-cycle evidence reconcile. Do not treat regulatory progress as a price floor.

Sources

Olin and Huntsman HSR expiry, September 11, 2026.
Olin-Huntsman merger terms, June 16, 2026.
HUN market reference, observed September 11, 2026 at 23:15:00Z.
OLN market reference, observed September 11, 2026 at 23:15:00Z.
EFSI-JMSB merger, September 7, 2026.

Research Quality Scorecard

Criterion	Score	Reason
Market disagreement	5/5	Clearance, synergy, fixed ratio, and break risk conflict clearly
Evidence base	5/5	Fresh HSR release, merger filing, and market references
Positioning and flows	2/5	Direct positioning unavailable
Catalyst path	5/5	Approvals, close, ratio, synergy, and deleveraging tests are observable
Payoff architecture	4/5	Explicit map, but base payoff is negative
Invalidation discipline	5/5	Close and operating tests are monitorable
Differentiated insight	5/5	Regulatory progress does not repair a negative spread
Client value	4/5	Defines when merger progress becomes value

Total: 35/40. Publishable research quality, but the 10/5 and ratio failures force Reject/no-trade classification.

Bottom Line

HSR expiry moves Olin-Huntsman closer to closing, but Huntsman's fixed 0.5476× exchange value is currently below its own market price. From a $9.54 reference, the base payoff is -1.26%, expected value is -8.00%, and gross reward to adverse risk is negative. The correct output is one substantive no-trade long screen, not an invented entry.

AI Illustration Prompt

Editorial financial illustration: two chemical plants joined by a fixed exchange-ratio chain, with a green regulatory stamp beside a red negative-spread gauge and a large synergy ledger fading into a debt stack; industrial blue, sulfur yellow, rust red, and cream palette; documentary realism, clean negative space, no trading interface, no price prediction; add a subtle readable “The Mispricing Desk” watermark in the lower-right corner.